Media coverage about Cidara Therapeutics (NASDAQ:CDTX) has been trending somewhat negative on Sunday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cidara Therapeutics earned a news sentiment score of -0.04 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.1787113569547 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Cidara Therapeutics (NASDAQ CDTX) traded down $0.05 during mid-day trading on Friday, reaching $7.30. The company’s stock had a trading volume of 56,326 shares, compared to its average volume of 78,248. The stock has a market capitalization of $148.75, a P/E ratio of -2.15 and a beta of 1.79. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.16. Cidara Therapeutics has a 52 week low of $5.60 and a 52 week high of $11.75.

Cidara Therapeutics (NASDAQ:CDTX) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.21. equities research analysts anticipate that Cidara Therapeutics will post -3.31 EPS for the current year.

Several research firms recently commented on CDTX. Zacks Investment Research lowered Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Cantor Fitzgerald set a $15.00 target price on Cidara Therapeutics and gave the stock a “buy” rating in a report on Tuesday, November 28th. Finally, HC Wainwright raised their target price on Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Cidara Therapeutics presently has an average rating of “Buy” and an average price target of $12.93.

In other Cidara Therapeutics news, major shareholder Target N. V. Biotech purchased 60,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were bought at an average price of $7.57 per share, for a total transaction of $454,200.00. Following the completion of the transaction, the insider now owns 2,295,272 shares of the company’s stock, valued at approximately $17,375,209.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 18.90% of the company’s stock.

WARNING: “Cidara Therapeutics (CDTX) Getting Somewhat Critical Press Coverage, Analysis Finds” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Insider Buying and Selling by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with's FREE daily email newsletter.